Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab in Pediatric Subjects With Active Chronic Pouchitis
NCT06443502Phase 3Recruiting
- Sponsor
- Takeda
- Start
- Nov 2024
- Primary completion
- Jan 2030
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 3 trial of vedolizumab in pouchitis, sponsored by Takeda. Started Nov 2024; status: recruiting.
02
Drugs
vedolizumab
03
Conditions
pouchitis
Beyond the preview
Go deeper on NCT06443502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06443502.